文献速递妇科

常规筛查年龄后宫颈癌的特征、治疗与生存:美国SEER-Medicare分析

Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
PubMed 文献 · Gynecol Oncol · 2022-02-01

基于SEER-Medicare 2004-2013年数据,描述2274例65岁以上宫颈癌患者特征、治疗与生存。中位年龄76.1岁,62.7%诊断时为II期及以上,14.6%未接受治疗,5年癌症特异性生存率为50%。年龄增长和分期增高与生存降低显著相关,治疗与生存提高强相关。

要点

  • 65岁以上宫颈癌患者中62.7%诊断时为II期及以上,23.1%为IV期。
  • 14.6%的患者未接受治疗,未治疗与高龄(>80岁)、合并症评分≥3及IV期疾病相关。
  • 5年癌症特异性生存率为50%,治疗与生存提高强相关。

核心结论

  • 大多数65岁以上宫颈癌患者诊断时即为局部晚期或转移性疾病,且许多未接受治疗。
  • 早期诊断和治疗可改善生存。
  • 作者认为,鉴于65岁以上女性人口比例增加,需重新评估该人群的筛查和治疗实践以早期发现宫颈癌并提高生存。

研究设计与样本

  • 使用SEER-Medicare 2004-2013年数据,描述2274例65岁以上诊断为宫颈癌的患者。
  • 采用Kaplan-Meier法估计5年癌症特异性生存率。
  • 采用多变量Poisson和Cox回归分析确定与治疗和死亡率相关的特征。

主要发现

  • 中位年龄76.1岁,近三分之一病例发生于80岁以上女性。
  • 大多数患者为非西班牙裔白人(64.8%),合并症评分≥1者占53.9%,鳞状组织学占66.3%。
  • 大多数女性诊断时为II期或更高(62.7%),包括近四分之一为IV期(23.1%)。
  • 近15%的患者未接受治疗(14.6%)。
  • 5年癌症特异性生存率为50%。

关键数值与推荐

  • 未治疗与最高年龄(>80岁)、合并症评分≥3及IV期疾病相关。
  • 年龄增长和诊断时分期增高与较低的癌症特异性生存显著相关,而治疗与生存提高强相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Given that cervical cancer incidence rates do not decline in women >65, there is generally limited screening, and these women have a poor prognosis, it is imperative to better understand this population. We aim to describe the characteristics, treatment, and survival of women >65 diagnosed with cervical cancer. METHODS: SEER-Medicare 2004-2013 data was used to describe 2274 patients >65 diagnosed with cervical cancer. Five-year cancer-specific survival was estimated using the Kaplan-Meier method. Multivariable Poisson and Cox regression analyses identified characteristics associated with treatment and mortality. RESULTS: The median age was 76.1 years, with nearly one-third of cases occurring in women >80 years. Most patients were non-Hispanic White (64.8%), had comorbidity scores ≥ 1 (53.9%) and squamous histology (66.3%). Most women were diagnosed at stage II or higher (62.7%), including nearly one-quarter at Stage IV (23.1%). Nearly 15% of patients were not treated (14.6%). Lack of treatment was associated with oldest age (>80), comorbidity scores ≥3, and stage IV disease. Five-year cancer-specific survival was 50%. Increasing age and stage at diagnosis were significantly associated with lower cancer-specific survival whereas treatment was strongly associated with increased survival. CONCLUSION: Most women >65 with cervical cancer are diagnosed with locally advanced or metastatic disease and many do not receive treatment. Survival is improved with early-stage diagnosis and treatment. These findings, coupled with the fact that women >65 constitute an increasing proportion of the population, highlight the need to re-evaluate screening and treatment practices in this population to detect cervical cancer at earlier stages and increase survival. NOVELTY AND IMPACT STATEMENT: In SEER-Medicare linked data from 2004 to 2013, most women >65 with cervical cancer were diagnosed with locally advanced or metastatic disease. Both receipt of treatment and survival decreased with increasing age. These findings, coupled with the fact that women aged >65 constitute an increasing proportion of the population, highlight the need to re-evaluate screening and treatment practices in older women to detect cervical cancer at earlier stages and increase survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lichter KE, Levinson K, Hammer A, et al. Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States. Gynecol Oncol. 2022. PMID: 35115179. doi:10.1016/j.ygyno.2022.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。